Skip to content

Return on equity at other companies

Pfizer logo
PfizerPFE
10.6%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-55.2%+8.0pp
CG Oncology logo
CG OncologyCGON
-20.8%+7.1pp
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-42.9%+1.3pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-197.8%-2,158pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-45.6%-66.1pp

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Calculated from Oric Pharmaceuticals, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s return on equity?
Oric Pharmaceuticals, Inc. (ORIC) reported return on equity of -42.6% in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s return on equity changed year-over-year?
Oric Pharmaceuticals, Inc.'s return on equity increased by 12.1% year-over-year, from -48.5% to -42.6%.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s return on equity?
Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s return on equity has grown at a 10.2% compound annual growth rate (CAGR), from -28% to -41.3%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.